To investigate potential differences in OPN levels in CSF among NMO and MS, Kariya et al. have measured the levels in patients with anti-AQP4-IgG-positive NMO and with MS (all at the relapse phase), as well as in the control group. The gene discussed is SPP1; the disease is myeloid sarcoma.